Rituximab and belimumab reached lupus low disease activity at similar rates

Design

Prospective single-centre observational registry cohort (BILAG-BR)

Population

176 people with SLE (175 rituximab and 58 belimumab courses)

Primary outcome

Low disease activity (SLEDAI-2K ≤4, prednisolone ≤5 mg/day)

Effect

Overlap-weighted HR 0.86 (95% CI 0.54–1.37); no difference

A single-centre UK registry followed 176 people with systemic lupus erythematosus treated with rituximab (175 courses) or belimumab (58 courses) between 2011 and 2025. The outcome was reaching low disease activity, defined as SLEDAI-2K of 4 or less on prednisolone 5 mg a day or less.

After adjustment, the two drugs did not differ in reaching low disease activity. Belimumab users started with more active disease. Drug survival was similar when either was the first biologic; as a second-line biologic, belimumab was continued longer.

This is observational, from a specialist centre, with few belimumab courses, and the two groups differed at baseline. It does not establish equivalence.

In practice, the choice between them is still guided by organ involvement, prior treatment, access and patient preference. Both are used in India, with cost a major factor.

• Choose between rituximab and belimumab by organ involvement, prior treatment and access.
• Define low disease activity as a treatment target, including steroid dose.
• Aim to reduce prednisolone to 5 mg a day or less.
• Review biologic choice when switching after a first agent fails.

Why it matters

Head-to-head data between these biologics are scarce, and this adds a real-world comparison.

Don't overread it

Single-centre observational data with baseline differences; it does not show the drugs are equivalent.

The statistics, in plain English

A hazard ratio of 0.86 with an interval from 0.54 to 1.37 is compatible with either drug being somewhat better; the study was too small to tell.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.